Evidence map›Paper›PMID 42918953›Full record

ArticleAnnals of surgical oncology2026

An International Randomized Prospective Trial Comparing a Supine MRI-based Guidance System, The Breast Cancer Locator

Jennifer S Gass, Sarah Pesek, Brian Czerniecki, Jessica Ryan, David Edmonson, Wey-Liang Leong, Jamie Patterson, Winne Polen, H E Guy Burman, Laila Samiian and 41 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

51 authors.

Jennifer S GassWomen and Infants' Hospital, Providence, RI, USA. jgass@wihri.org.
Sarah PesekSt Peter's Health Partners Cancer Care Center, USA, Albany.
Brian CzernieckiMoffitt Cancer Center, Tampa, USA.
Jessica RyanCatholic Medical Center, Manchester, USA.
David EdmonsonTufts Medical Center, Boston, USA.
Wey-Liang LeongPrincess Margaret Cancer Centre, Toronto, Canada.
Jamie PattersonWoman's Hospital, Baton Rouge, USA.
Winne PolenSummit Health, Florham Park, USA.
H E Guy BurmanCheshire Medical Center, Keene, USA.
Laila SamiianBaptist MD Anderson Cancer Center, Jacksonville, USA.
Rebecca KwaitMassachusetts General Hospital, Danvers, USA.
Richard EhlersThe University of Texas MD Anderson Cancer Center, Houston, USA.
Kelly HuntThe University of Texas MD Anderson Cancer Center, Houston, USA.
Abigail MadansHennepin Healthcare, Minneapolis, USA.
Bret TabackNew York-Presbyterian/Columbia University Irving Medical Center, New York, USA.
Kari RosenkranzDartmouth-Hitchcock Medical Center, Lebanon, USA.
Karen Ching-TismalBaptist MD Anderson Cancer Center, Jacksonville, USA.
James HarveyUniversity Hospital South Manchester NHS Foundation Trust, Manchester, UK.
Catherine AkayThe University of Texas MD Anderson Cancer Center, Houston, USA.
Boris BronfineDartmouth-Hitchcock Clinics Nashua, Nashua, USA.
Nazanin KhakpourMoffitt Cancer Center, Tampa, USA.
Abhishek ChatterjeeTufts Medical Center, Boston, USA.
Angelika Wolfrum, Feldkirch Landeskrankenhaus, Feldkirch, Austria.
Sumohan ChatterjeeUniversity Hospital South Manchester NHS Foundation Trust, Manchester, UK.
William DiehlSummit Health, Florham Park, USA.
Lucinda GuerraCheshire Medical Center, Keene, USA.
Kerry BennettReliant Medical Group, Worcester, USA.
Suzanne CoopeyAllegheny Health Network, Pittsburgh, USA.
Sommer GuniaComprehensive Breast Center of Arizona, Scottsdale, USA.
Stacey AbbisDartmouth-Hitchcock Clinics Nashua, Nashua, USA.
Gabriel KaufmanSt Peter's Health Partners Cancer Care Center, USA, Albany.
Andrew LoehrerDartmouth-Hitchcock Medical Center, Lebanon, USA.
Abdalla Saad Abdalla Al-ZawiBasildon Hospital, Essex, United Kingdom of Great Britain and Northern Ireland.
Susie X SunThe University of Texas MD Anderson Cancer Center, Houston, USA.
Rajiv DaveUniversity Hospital South Manchester NHS Foundation Trust, Manchester, UK.
Ryan DeislerHennepin Healthcare, Minneapolis, USA.
Micaela WeaverKent Hospital, Warwick, RI, USA.
D Wayne ChickenBasildon Hospital, Essex, United Kingdom of Great Britain and Northern Ireland.
Constanza CocilovoInova Schar Cancer Institute, Fairfax, USA.
Urvashi JainUniversity Hospital South Manchester NHS Foundation Trust, Manchester, UK.
Sharita NagarajNorthern Arizona Healthcare, Cottonwood, USA.
Sarah PersingTufts Medical Center, Boston, USA.
Jennifer TonnesonDartmouth-Hitchcock Medical Center, Lebanon, USA.
Burghard Abendstein, Feldkirch Landeskrankenhaus, Feldkirch, Austria.
Shawna WilleyInova Schar Cancer Institute, Fairfax, USA.
Timothy RooneyUniversity of Virginia Health, Charlottesville, USA.
Helene Cauwel-SchryveCytel, Inc., Geneva, Switzerland.
Misty FoxCairn Surgical, Inc., Lebanon, USA.
Venkataramanan KrishnaswamyCairn Surgical, Inc., Lebanon, USA.
Keith PaulsenDartmouth-Hitchcock Medical Center, Lebanon, USA.
Richard J BarthDartmouth-Hitchcock Medical Center, Lebanon, USA.

Funding

NCI NIH HHS Award Number R44CA247124
6 · The paper itself

Abstract

backgroundPositive margins after breast-conserving surgery (BCS) require additional surgery, a negative patient experience that also adds costs to care. Pilot trials indicate the Breast Cancer Locator

methodsPatients with nonpalpable, magnetic resonance imaging-visualized invasive breast cancer or ductal carcinoma in situ undergoing BCS were prospectively randomized to either BCL or WL.

resultsIn total, 418 randomized patients underwent surgery. The PMR was 14.4% (30/209) in the BCL group and 21.1% (44/209) in the WL group, a relative decrease of 32%. In primary analysis, the treatment difference was -7.1% (95.4% confidence interval [CI] -14.3 to 0.1). Noninferiority was demonstrated (p = 0.011). The one-sided p-value for superiority (p = 0.025) slightly exceeded the prespecified significance level of 0.023. In prespecified analysis stratified by final tumor type, the PMR was significantly lower in the BCL group (p = 0.019). Fewer BCL patients underwent re-excision: 12.9% versus 19.6%, a relative decrease of 34%. The PMR for all tumor types was lower in the BCL group, with a > 60% relative reduction in PMR in patients with ductal carcinoma in situ (20.6% vs. 53.3% [95% CI -52.1 to -9.1]) and invasive lobular carcinoma (9.1% vs. 25.6% [95% CI -32.9 to -0.2]). Adverse event rates were similar.

conclusionsBCL was noninferior to WL and superior in analysis stratified by final tumor type. Clinically meaningful relative reductions in PMR and re-excision rates were observed.

Indexed as

Breast cancerDCISMarginMRISupine

Identifiers

PMID42918953

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.